From this perspective, local administration into the CNS of highly specific and stable exon 41 skipping ASOs with a potential for therapeutic effect on pathogenic LRRK2 kinase activity is an attractive treatment strategy for PD patients. The gene discussed is LRRK2; the disease is Parkinson disease.